Related Experiment Video
Updated: Jul 4, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
User trial of Easypod, an electronic autoinjector for growth hormone
M Tauber1, C Payen, A Cartault
1Unité d'Endocrinologie, Maladies Osseuses, Génétique et Gynécologie Médicale, Hôpital des Enfants, CHU Toulouse, TSA, Toulouse cedex 9, France. tauber.mt@chu-toulouse.fr
Objective:
A new electronic injection device, the Easypod, has been developed to administer growth hormone (GH). This study assessed the use of this device in common practice.
Materials And Methods:
Results are from the French arm (one centre) of an international, open-label, uncontrolled study. Subjects were children already using, or about to start, GH therapy. Children used the Easypod device for 60 days. The main outcome measures were patients' or, if appropriate, their parents' qualitative overall impression of the device and the usefulness of its features after 15 days' use, as evaluated by questionnaire.
Results:
At day 15, all participants (20/20) described their overall impression of the Easypod device as "good" or "very good". All participants rated the display of the remaining drug in the cartridge, the preprogrammed dosing, the onscreen instructions and the automatic-needle attachment as "useful" or "very useful". The device's audible/visible signals and customisable injection depth and speed were each rated as "useful" or "very useful" by 19/20 participants and the skin sensor, customisable needle-insertion speed and dose-injection confirmation were each rated as such by 18/20 participants. Electronic display of the date and time of the last injection and the dose history were considered "useful" or "very useful" by 17/20 and 15/20 participants, respectively. At day 60, 17/17 respondents expressed a preference for continuing to use the device.
Conclusion:
These results show that the features of Easypod are considered useful in routine practice and the majority of participants expressed a desire to continue using the device.
Related Concept Videos
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Drug Dosing: Obese Patients
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Dosing: Infants and Children

